2026 Q1 -tulosraportti
46 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,99%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 900 | - | - | ||
| 780 | - | - | ||
| 211 | - | - | ||
| 799 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·13 min sittenNew research presented at the annual endocrinology congress, ENDO 2026, suggests that GLP-1 weight loss medication may have a positive effect on male fertility. The researchers investigated the link between obesity and fertility problems in men. Overweight can disrupt the body's hormonal system (the HPG axis), which controls testosterone production, and can lead to functional hypogonadism, where testosterone levels are abnormally low. This can simultaneously impair sperm quality. In a review of five randomized clinical trials, the effect of GLP-1 medication on hormones, sperm quality, and metabolism was investigated in men aged 18 to 65. The results showed that GLP-1 treatment: * Does not appear to suppress male sex hormones. * Can increase testosterone levels in overweight men with low testosterone. * Can improve sperm quality, sperm concentration, and sperm count. * Can improve metabolic factors such as weight, BMI, cholesterol, and blood sugar. Among the investigated drugs: * Dulaglutide showed no significant changes in reproductive hormones or sexual function after four weeks. * Liraglutide improved hormone levels in overweight men with functional hypogonadism and yielded better overall health outcomes than testosterone replacement therapy (TRT) in one of the studies. * Semaglutide improved sperm morphology and LDL cholesterol, while preserving testosterone levels. The researchers emphasize, however, that the evidence is still limited, as the analysis only included five studies. There is therefore a need for larger and more targeted studies to confirm the effect on male fertility. An external expert assesses that if the results are confirmed in future research, GLP-1 medication could become an attractive alternative to testosterone treatment in overweight men with low testosterone, because GLP-1 treatment appears to preserve fertility, while testosterone replacement therapy can often reduce sperm production.- ·9 t sittenNovo Nordisk's CEO, Mike Doustdar, confirmed for the first time that semaglutide's data protection period in China will last until Q2 2027 June 20 China Fund News reported on June 20 that Novo Nordisk's CEO, Mike Doustdar, confirmed for the first time that the data protection period for semaglutide in China will continue until Q2 2027. After this time, generic versions can be legally marketed. This "extra exclusivity period" of more than one year is based on the free trade agreement between China and Switzerland and not on Chinese national legislation. Although more than 10 Chinese pharmaceutical companies have already submitted applications for generic versions, the expected approvals have not yet been realized.
·9 t sittenI own the stock myself, but I'm worried that the hacker attack could destroy Novo. And even if it doesn't, it really seems amateurish that it could have happened.
·6 t sittenZoid. If someone buys this data, then you should remember it's just as illegal to copy as it is to buy. And it MUST be approved and their product made in precisely the same way as Novo, otherwise the company will most likely close, meaning those who have copied.·1 t sittenI hope you are right. However, I'm not entirely sure how they will protect their research on products not yet published or their AI model. If Novo doesn't have a patent, then a 'Chinese' company could coincidentally come up with the same thing. And again, I hope you are right.
·17 t sittenBernstern and Nordea have upgraded their expectations for Novo's share price. They do this partly by looking at the prescription numbers and do the math. Their assessment is therefore based on facts and not so much an estimate.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
46 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,99%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13 min sittenNew research presented at the annual endocrinology congress, ENDO 2026, suggests that GLP-1 weight loss medication may have a positive effect on male fertility. The researchers investigated the link between obesity and fertility problems in men. Overweight can disrupt the body's hormonal system (the HPG axis), which controls testosterone production, and can lead to functional hypogonadism, where testosterone levels are abnormally low. This can simultaneously impair sperm quality. In a review of five randomized clinical trials, the effect of GLP-1 medication on hormones, sperm quality, and metabolism was investigated in men aged 18 to 65. The results showed that GLP-1 treatment: * Does not appear to suppress male sex hormones. * Can increase testosterone levels in overweight men with low testosterone. * Can improve sperm quality, sperm concentration, and sperm count. * Can improve metabolic factors such as weight, BMI, cholesterol, and blood sugar. Among the investigated drugs: * Dulaglutide showed no significant changes in reproductive hormones or sexual function after four weeks. * Liraglutide improved hormone levels in overweight men with functional hypogonadism and yielded better overall health outcomes than testosterone replacement therapy (TRT) in one of the studies. * Semaglutide improved sperm morphology and LDL cholesterol, while preserving testosterone levels. The researchers emphasize, however, that the evidence is still limited, as the analysis only included five studies. There is therefore a need for larger and more targeted studies to confirm the effect on male fertility. An external expert assesses that if the results are confirmed in future research, GLP-1 medication could become an attractive alternative to testosterone treatment in overweight men with low testosterone, because GLP-1 treatment appears to preserve fertility, while testosterone replacement therapy can often reduce sperm production.
- ·9 t sittenNovo Nordisk's CEO, Mike Doustdar, confirmed for the first time that semaglutide's data protection period in China will last until Q2 2027 June 20 China Fund News reported on June 20 that Novo Nordisk's CEO, Mike Doustdar, confirmed for the first time that the data protection period for semaglutide in China will continue until Q2 2027. After this time, generic versions can be legally marketed. This "extra exclusivity period" of more than one year is based on the free trade agreement between China and Switzerland and not on Chinese national legislation. Although more than 10 Chinese pharmaceutical companies have already submitted applications for generic versions, the expected approvals have not yet been realized.
- ·9 t sittenI own the stock myself, but I'm worried that the hacker attack could destroy Novo. And even if it doesn't, it really seems amateurish that it could have happened.·6 t sittenZoid. If someone buys this data, then you should remember it's just as illegal to copy as it is to buy. And it MUST be approved and their product made in precisely the same way as Novo, otherwise the company will most likely close, meaning those who have copied.·1 t sittenI hope you are right. However, I'm not entirely sure how they will protect their research on products not yet published or their AI model. If Novo doesn't have a patent, then a 'Chinese' company could coincidentally come up with the same thing. And again, I hope you are right.
- ·17 t sittenBernstern and Nordea have upgraded their expectations for Novo's share price. They do this partly by looking at the prescription numbers and do the math. Their assessment is therefore based on facts and not so much an estimate.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 900 | - | - | ||
| 780 | - | - | ||
| 211 | - | - | ||
| 799 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
46 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,99%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13 min sittenNew research presented at the annual endocrinology congress, ENDO 2026, suggests that GLP-1 weight loss medication may have a positive effect on male fertility. The researchers investigated the link between obesity and fertility problems in men. Overweight can disrupt the body's hormonal system (the HPG axis), which controls testosterone production, and can lead to functional hypogonadism, where testosterone levels are abnormally low. This can simultaneously impair sperm quality. In a review of five randomized clinical trials, the effect of GLP-1 medication on hormones, sperm quality, and metabolism was investigated in men aged 18 to 65. The results showed that GLP-1 treatment: * Does not appear to suppress male sex hormones. * Can increase testosterone levels in overweight men with low testosterone. * Can improve sperm quality, sperm concentration, and sperm count. * Can improve metabolic factors such as weight, BMI, cholesterol, and blood sugar. Among the investigated drugs: * Dulaglutide showed no significant changes in reproductive hormones or sexual function after four weeks. * Liraglutide improved hormone levels in overweight men with functional hypogonadism and yielded better overall health outcomes than testosterone replacement therapy (TRT) in one of the studies. * Semaglutide improved sperm morphology and LDL cholesterol, while preserving testosterone levels. The researchers emphasize, however, that the evidence is still limited, as the analysis only included five studies. There is therefore a need for larger and more targeted studies to confirm the effect on male fertility. An external expert assesses that if the results are confirmed in future research, GLP-1 medication could become an attractive alternative to testosterone treatment in overweight men with low testosterone, because GLP-1 treatment appears to preserve fertility, while testosterone replacement therapy can often reduce sperm production.
- ·9 t sittenNovo Nordisk's CEO, Mike Doustdar, confirmed for the first time that semaglutide's data protection period in China will last until Q2 2027 June 20 China Fund News reported on June 20 that Novo Nordisk's CEO, Mike Doustdar, confirmed for the first time that the data protection period for semaglutide in China will continue until Q2 2027. After this time, generic versions can be legally marketed. This "extra exclusivity period" of more than one year is based on the free trade agreement between China and Switzerland and not on Chinese national legislation. Although more than 10 Chinese pharmaceutical companies have already submitted applications for generic versions, the expected approvals have not yet been realized.
- ·9 t sittenI own the stock myself, but I'm worried that the hacker attack could destroy Novo. And even if it doesn't, it really seems amateurish that it could have happened.·6 t sittenZoid. If someone buys this data, then you should remember it's just as illegal to copy as it is to buy. And it MUST be approved and their product made in precisely the same way as Novo, otherwise the company will most likely close, meaning those who have copied.·1 t sittenI hope you are right. However, I'm not entirely sure how they will protect their research on products not yet published or their AI model. If Novo doesn't have a patent, then a 'Chinese' company could coincidentally come up with the same thing. And again, I hope you are right.
- ·17 t sittenBernstern and Nordea have upgraded their expectations for Novo's share price. They do this partly by looking at the prescription numbers and do the math. Their assessment is therefore based on facts and not so much an estimate.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 900 | - | - | ||
| 780 | - | - | ||
| 211 | - | - | ||
| 799 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt